glucose utilization inhibitor (IGU)

09/01/2023 - "We aim to explore efficacy of combined use of MTX and IGU for female patients with rheumatoid arthritis and its impact on ovarian reserve function. "
05/01/2015 - "The first clinical study of IGU in Japanese patients with rheumatoid arthritis was started in 1992 and Phase III studies were started in 1998. "
09/01/2023 - "Total 80 female patients with moderate to severe active rheumatoid arthritis were selected and randomly divided into MTX and MTX + IGU groups. "
06/01/2016 - "IGU can be used in wide variety of situation of the treatment of rheumatoid arthritis and it is desired that after the all-case surveillance condition for approval, IGU become a standard csDMARDs all over the world which was made in Japan."
01/01/2023 - "IGU (IGU), a novel immunomodulatory agent for rheumatoid arthritis, has been shown to be effective and safe as monotherapy in a small population with refractory lupus nephritis (LN). "

10/01/2021 - "Furthermore, IGU ameliorated TNF-α-induced severe pulmonary fibrosis and inhibited TNF-α-induced activation of NF-κB. "
10/01/2021 - "IGU reduced TNF-α production in the pulmonary fibrosis murine model and in the in vitro cultured A549 cells. "
04/01/2019 - "IGU can decrease BLM-induced pulmonary fibrosis, and the anti-fibrotic effect of IGU is mediated partly via inhibition of MMP-9, which suggests that IGU could potentially be an effective therapeutic strategy for pulmonary fibrosis."
09/01/2022 - "Clinical studies have found that IGU has certain advantages in improving lung function and shows great potential for pulmonary fibrosis therapy. "
08/01/2021 - "IGU reduced BLM-induced changes in pulmonary fibrosis and pulmonary inflammation, as shown in histological examination.Collagen"

01/01/2023 - "This study aims to assess the efficacy of tofacitinib (TOF) plus iguratimod (IGU) in rheumatoid arthritis (RA) with usual interstitial pneumonia (UIP) (RA-UIP). "

01/01/2023 - "After 6 months of TOF plus IGU treatment, forced vital capacity (FVC)% (84.7 ± 14.7 vs. 90.7 ± 15.4) and HRCT fibrosis score (7.3 ± 3.4 vs. 7.0 ± 5.6) showed a significant improvement compared to the csDMARDs group (P = 0.031, P = 0.015). "
04/01/2019 - "Both the pathological alveolitis and fibrosis scores in the drug-treated groups (IGU group, MP group and PF group) were decreased dramatically compared with the BLM group on day 7, 14 and 28 (P < 0.05). "
09/01/2022 - " then found that the anti-lung fibrosis effect of IGU was accompanied by a decrease in reactive oxygen species (ROS) production. "
08/01/2021 - "IGU inhibits immunoglobulin secretion by B cells to relieve pulmonary inflammation and fibrosis. "
10/01/2021 - "We found IGU decreased pulmonary inflammation and fibrosis and expression of fibrosis-related genes such as Collagen I, α-smooth muscle actin (α-SMA) and matrix metalloproteinase-2 (MMP-2) induced by bleomycin. "

06/01/2021 - "The data indicate that IGU-PLGA-NPs induce a significant reduction in the tumour volume and a marked increase in the survival rate in a mouse model of multiple myeloma. "
09/07/1980 - "[IgU (lambda) type multiple myeloma associated with amyloidosis]."
07/01/1979 - "It has been published a case of amyloidosis with multiple myeloma IgU/lamba/. "